Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond

Durvalumab is the first approved adjuvant immunotherapy agent for patients with stage III NSCLC treated with concurrent chemoradiotherapy and is associated with improved overall survival. In order to minimise the number of hospital visits for patients receiving durvalumab during the COVID-19 pandemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Kroopa, Muhith, Abdul, Obeid, Mariam, Milner-Watts, Charlotte, Yousaf, Nadia, Popat, Sanjay, Davidson, Michael, Bhosle, Jaishree, O’Brien, Mary, Minchom, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086258/
https://www.ncbi.nlm.nih.gov/pubmed/33965281
http://dx.doi.org/10.1016/j.lungcan.2021.04.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086258/
https://www.ncbi.nlm.nih.gov/pubmed/33965281
http://dx.doi.org/10.1016/j.lungcan.2021.04.021

Ejemplares similares